John C. Reed's Insider Trades & SAST Disclosures
John C. Reed's most recent trade in Johnson & Johnson was a trade of 25,255 Restricted Share Units done . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John C. Reed.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 25,255 | 25,255 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 25,255 | 40,797 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.31 per share. | 01 May 2025 | 11,002 | 29,795 (0%) | 0% | 156.3 | 1,719,723 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 15,927 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 2,698 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 15 Feb 2025 | 385 | 15,542 (0%) | 0% | 156.2 | 60,118 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 50,510 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 25,561 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 53,510 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 22,561 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 11,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 14,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 65,163 | 65,163 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | C. John Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,048 | 4,048 | - | - | Restricted Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges